{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T23:51:57Z","timestamp":1769039517304,"version":"3.49.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T00:00:00Z","timestamp":1684886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T00:00:00Z","timestamp":1684886400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s00115-023-01490-8","type":"journal-article","created":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T15:02:27Z","timestamp":1684940547000},"page":"510-518","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Myositis: von der Diagnose zur Therapie","Myositis: from diagnosis to treatment"],"prefix":"10.1007","volume":"94","author":[{"given":"Jens","family":"Schmidt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"M\u00fcller-Felber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,5,24]]},"reference":[{"key":"1490_CR1","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3233\/JND-180308","volume":"5","author":"J Schmidt","year":"2018","unstructured":"Schmidt\u00a0J (2018) Current classification and management of inflammatory myopathies. J\u00a0Neuromuscul Dis 5:109\u2013129","journal-title":"J Neuromuscul Dis"},{"key":"1490_CR2","unstructured":"Wiendl\u00a0H, Schmidt\u00a0J et al (2022) Myositissyndrome, S2k-Leitlinie;  in: Deutsche Gesellschaft f\u00fcr Neurologie (Hrsg.), Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie. https:\/\/www.dgn.org\/leitlinien. Zugegriffen: 23.05.2023"},{"key":"1490_CR3","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1002\/art.40063","volume":"69","author":"JL Senecal","year":"2017","unstructured":"Senecal\u00a0JL, Raynauld\u00a0JP, Troyanov\u00a0Y (2017) Editorial: a new classification of adult autoimmune myositis. Arthritis Rheumatol 69:878\u2013884","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"1490_CR4","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s00408-016-9896-x","volume":"194","author":"C Johnson","year":"2016","unstructured":"Johnson\u00a0C, Pinal-Fernandez\u00a0I, Parikh\u00a0R et al (2016) Assessment of mortality in autoimmune myositis with and without associated interstitial lung diseas. Lung 194(5):733\u2013737","journal-title":"Lung"},{"issue":"87","key":"1490_CR5","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1212\/WNL.0000000000002863","volume":"19","author":"A Hida","year":"2016","unstructured":"Hida\u00a0A, Yamashita\u00a0T, Hosono\u00a0Y et al (2016) Anti-TIF1-gamma antibody and cancer-associated myositis: a clinicohistopathologic study. Neurology 19(87):299\u2013308","journal-title":"Neurology"},{"key":"1490_CR6","first-page":"377","volume":"38","author":"P Korsten","year":"2019","unstructured":"Korsten\u00a0P, Rademacher\u00a0JG, Seitz\u00a0CS et al (2019) Interdisziplin\u00e4re Fallkonferenz als Chance f\u00fcr Myositis-Patienten? \u2013 Retrospektive Analyse des \u201eG\u00f6ttinger Modells\u201c zur interdisziplin\u00e4ren Diagnostik und Therapie. Nervenheilkunde 38:377\u2013380","journal-title":"Nervenheilkunde"},{"key":"1490_CR7","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1002\/art.40320","volume":"69","author":"IE Lundberg","year":"2017","unstructured":"Lundberg\u00a0IE, Tjarnlund\u00a0A, Bottai\u00a0M et\u00a0al (2017) 2017 European league against rheumatism\/American college of rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Arthritis Rheumatol 69:2271\u20132282","journal-title":"Arthritis Rheumatol"},{"key":"1490_CR8","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.nmd.2004.02.006","volume":"14","author":"JE Hoogendijk","year":"2004","unstructured":"Hoogendijk\u00a0JE, Amato\u00a0AA, Lecky\u00a0BR et\u00a0al (2004) 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10\u201312 October 2003, Naarden, The Netherlands. Neuromuscul Disord 14:337\u2013345","journal-title":"Neuromuscul Disord"},{"key":"1490_CR9","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.nmd.2013.08.007","volume":"23","author":"MR Rose","year":"2013","unstructured":"Rose\u00a0MR (2013) 188th ENMC international workshop: inclusion body myositis, 2\u20134 december 2011, Naarden, The Netherlands. Neuromuscul Disord 23:1044\u20131055","journal-title":"Neuromuscul Disord"},{"key":"1490_CR10","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1002\/art.40064","volume":"69","author":"R Aggarwal","year":"2017","unstructured":"Aggarwal\u00a0R, Rider\u00a0LG, Ruperto\u00a0N et\u00a0al (2017) 2016 American College of Rheumatology\/European League against Rheumatism criteria for minimal, moderate, and major clinical response in adult Dermatomyositis and Polymyositis: an international myositis assessment and clinical studies group\/paediatric rheumatology international trials organisation collaborative initiative. Arthritis Rheumatol 69:898\u2013910","journal-title":"Arthritis Rheumatol"},{"key":"1490_CR11","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/nrrheum.2018.48","volume":"14","author":"FW Miller","year":"2018","unstructured":"Miller\u00a0FW, Lamb\u00a0JA, Schmidt\u00a0J et\u00a0al (2018) Risk factors and disease mechanisms in myositis. Nat Rev Rheumatol 14:255\u2013268","journal-title":"Nat Rev Rheumatol"},{"key":"1490_CR12","doi-asserted-by":"publisher","first-page":"101764","DOI":"10.1016\/j.berh.2022.101764","volume":"36","author":"SF Bhai","year":"2022","unstructured":"Bhai\u00a0SF, Dimachkie\u00a0MM, de Visser\u00a0M (2022) Is it really myositis? Mimics and pitfalls. Best Pract Res Clin Rheumatol 36:101764","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"1490_CR13","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1097\/BOR.0000000000000436","volume":"29","author":"K Schmidt","year":"2017","unstructured":"Schmidt\u00a0K, Schmidt\u00a0J (2017) Inclusion body myositis: advancements in diagnosis, pathomechanisms, and treatment. Curr Opin Rheumatol 29:632\u2013638","journal-title":"Curr Opin Rheumatol"},{"key":"1490_CR14","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1093\/jnen\/63.5.484","volume":"63","author":"I Ferrer","year":"2004","unstructured":"Ferrer\u00a0I, Martin\u00a0B, Castano\u00a0JG et\u00a0al (2004) Proteasomal expression, induction of immunoproteasome subunits, and local MHC class I presentation in myofibrillar myopathy and inclusion body myositis. J\u00a0Neuropathol Exp Neurol 63:484\u2013498","journal-title":"J Neuropathol Exp Neurol"},{"key":"1490_CR15","doi-asserted-by":"publisher","first-page":"600","DOI":"10.3390\/cells11040600","volume":"11","author":"R Abdelnaby","year":"2022","unstructured":"Abdelnaby\u00a0R, Mohamed\u00a0KA, Elgenidy\u00a0A et al (2022) Muscle sonography in inclusion body myositis: a systematic review and meta-analysis of 944 measurements. Cells 11:600","journal-title":"Cells"},{"key":"1490_CR16","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1093\/rheumatology\/kez313","volume":"58","author":"P Korsten","year":"2019","unstructured":"Korsten\u00a0P, Seitz\u00a0CS, Sahlmann\u00a0CO et al (2019) Comment on: The temporal relationship between cancer and adult onset anti-transcriptional intermediary factor 1 antibody-positive dermatomyositis. Rheumatol (Oxford) 58:2071\u20132073","journal-title":"Rheumatol (Oxford)"},{"key":"1490_CR17","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1212\/WNL.0000000000003337","volume":"87","author":"A Olthoff","year":"2016","unstructured":"Olthoff\u00a0A, Carstens\u00a0PO, Zhang\u00a0S et al (2016) Evaluation of dysphagia by novel real-time MRI. Neurology 87:2132\u20132138","journal-title":"Neurology"},{"key":"1490_CR18","doi-asserted-by":"publisher","first-page":"863","DOI":"10.2174\/1381612827666211115165353","volume":"28","author":"S Glaubitz","year":"2022","unstructured":"Glaubitz\u00a0S, Zeng\u00a0R, Rakocevic\u00a0G et\u00a0al (2022) Update on myositis therapy: from today\u2019s standards to tomorrow\u2019s possibilities. Curr Pharm Des 28:863\u2013880","journal-title":"Curr Pharm Des"},{"key":"1490_CR19","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s40674-020-00168-5","volume":"7","author":"LM Pachman","year":"2021","unstructured":"Pachman\u00a0LM, Nolan\u00a0BE, DeRanieri\u00a0D et\u00a0al (2021) Juvenile dermatomyositis: new clues to diagnosis and therapy. Curr Treatm Opt Rheumatol 7:39\u201362","journal-title":"Curr Treatm Opt Rheumatol"},{"key":"1490_CR20","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1056\/NEJMoa2117912","volume":"387","author":"R Aggarwal","year":"2022","unstructured":"Aggarwal\u00a0R, Charles-Schoeman\u00a0C, Schessl\u00a0J et al (2022) Trial of intravenous immune globulin in dermatomyositis. N\u00a0Engl J Med 387:1264\u20131278","journal-title":"N Engl J Med"},{"key":"1490_CR21","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s11926-020-00950-3","volume":"22","author":"R Zeng","year":"2020","unstructured":"Zeng\u00a0R, Schmidt\u00a0J (2020) Impact and management of dysphagia in inflammatory myopathies. Curr Rheumatol Rep 22:74","journal-title":"Curr Rheumatol Rep"},{"key":"1490_CR22","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1007\/s13311-022-01220-z","volume":"19","author":"R Zeng","year":"2022","unstructured":"Zeng\u00a0R, Glaubitz\u00a0S, Schmidt\u00a0J (2022) Antibody therapies in autoimmune inflammatory myopathies: promising treatment options. Neurotherapeutics 19:911\u2013921","journal-title":"Neurotherapeutics"},{"key":"1490_CR23","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1080\/13543784.2021.2003776","volume":"30","author":"R Zeng","year":"2021","unstructured":"Zeng\u00a0R, Glaubitz\u00a0S, Schmidt\u00a0J (2021) Inflammatory myopathies: shedding light on promising agents and combination therapies in clinical trials. Expert Opin Investig Drugs 30:1125\u20131140","journal-title":"Expert Opin Investig Drugs"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-023-01490-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00115-023-01490-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-023-01490-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T14:07:07Z","timestamp":1686319627000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00115-023-01490-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,24]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["1490"],"URL":"https:\/\/doi.org\/10.1007\/s00115-023-01490-8","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"value":"0028-2804","type":"print"},{"value":"1433-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,24]]},"assertion":[{"value":"3 April 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"J.\u00a0Schmidt hat Beraterhonorare, Reisekostenerstattungen oder Projektf\u00f6rderungen erhalten von Abcuro, Alnylam, Argenx, Biotest, CSL Behring, Euroimmun, Janssen, Kezar, LFB, Novartis, Octapharma, UCB. W.\u00a0M\u00fcller-Felber hat Beraterhonorare, Reisekostenerstattungen und Vortragshonorare erhalten von Biogen, Novartis, Roche, Sarepta, PTC, Sanofi-Aventis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}